Finally, the anti-CD52 antibody alemtuzumab has also demonstrated efficacy in CLL, though it was associated with lower efficacy and greater adverse effects when compared with rituximab in a phase III trial [237]. The gene discussed is CD52; the disease is B-cell chronic lymphocytic leukemia.